Atty. Docket No.: 8039/1090 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Riechmann, et al.	Examiner:	B. Celsa
Serial No.:	09/710,444	Group Art Unit:	1627
Filed:	November 10, 2000	Conf. No.:	2736
Entitled:	"Selection System"		

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to: U.S. Patent & Trademark Office, Box: Sequence, P.O. Box 2327, Arlington, VA 22202.

Mary Wilson
Name of Person Mailing Paper

Signature of Person Mailing Paper

10-10-02

U.S. Patent and Trademark Office
Box: Sequence
P.O. Box 2327
Arlington, VA 22202

AMENDMENT

Sir:

This is filed in response to the Examiner's Notice to Comply with nucleotide or amino acid sequence listing requirements mailed February 27, 2002 in the above noted U.S. Patent Application. Kindly enter the following amendments and remarks.

In the Specification:

Replace the paragraph at lines 14 to 23 on page 15 with the following replacement paragraph:

A sequence (PAGLSEGSTIEGRGAHE; SEQ ID NO: 1) comprising several proteolytic sites is inserted in the flexible glycine-rich region between the D2 and D3 domains of the phage p3. Incubation of the phage (fd-K108) under native conditions with trypsin, thermolysin or subtilisin now resulted in almost complete loss of infectivity (from 10^7 to < 10 TU/ml) and incubation with Glu-C and chymotrypsin resulted in a major loss (from 10^7 to 10^4 TU/ml). This indicates that these proteases cleave the new linker. However incubation with Factor Xa, Arg-C or thrombin did not lead to a loss in infectivity, despite the presence of potential cleavage sites